FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077880120> ?p ?o ?g. }

• W2077880120 abstract "Introduction: The pharmacokinetics and safety of casopitant, a neurokinin‐1 receptor antagonist being developed for the prevention of chemotherapy‐induced and post‐operative nausea and vomiting, were evaluated in subjects with mild (Child‐Pugh score of 5–6) and moderate (Child‐Pugh score of 7–9) hepatic impairment; mild (creatinine clearance 50–80 mL/min) and moderate (creatinine clearance 30–49 mL/min) renal impairment; and subjects with normal hepatic and renal function. Experimental Design: Twenty‐six subjects were enrolled in the hepatic impairment study (9 mild, 9 moderate and 8 normal subjects) and 18 subjects in the renal impairment study (6 mild, 6 moderate and 6 normal subjects). Subjects with severe hepatic or renal impairment were excluded. All subjects received a once‐daily dose of 100 mg oral casopitant for 5 days. Pharmacokinetics and plasma protein binding of casopitant and its major metabolite, GSK525060, were determined on Days 1 and 5. Safety was continuously assessed. Results: Subjects with mild or moderate hepatic impairment had an increase in casopitant AUC of 11% and 24%, respectively, on Day 1 compared with normal subjects; a similar increase was observed on Day 5. Casopitant Cmax was variable, but similar across all subjects. GSK525060 AUC was not significantly different between normal subjects and subjects with mild hepatic impairment; however, AUC was reduced 29% and 19% on Days 1 and 5, respectively, in subjects with moderate hepatic impairment. The percent bound of casopitant and GSK525060 was similar in all subjects. Casopitant AUC increased 34% and 22% in subjects with mild or moderate renal impairment on Day 1, respectively, and 28% and 11% on Day 5, respectively, when compared with normal subjects. GSK525060 AUC increased 17% and 24% on Days 1 and 5, respectively, in subjects with mild renal impairment, but did not significantly change in subjects with moderate impairment. Further age‐adjusted analysis showed no meaningful effect of renal impairment on casopitant or GSK525060 AUC. Cmax and half‐life in renal impaired subjects were similar to normal subjects. The plasma protein‐binding of casopitant and GSK525060 was similar in all subjects. Casopitant was well tolerated, with no significant difference in the type or frequency of adverse events (AEs) noted between subjects with mild, moderate or no hepatic or renal impairment. Somnolence, flatulence and nausea were the most frequently reported AEs in the hepatic impairment study; whereas constipation and dyspepsia were the most frequently reported events in the renal impairment study. No AEs were reported in subjects with mild renal impairment. Conclusion: The pharmacokinetics of casopitant is not altered to a clinically significant extent in subjects with mild or moderate, hepatic or renal impairment. The impact of severe hepatic or renal impairment on the pharmacokinetics and safety of casopitant was not evaluated. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C132." @default.
• W2077880120 created "2016-06-24" @default.
• W2077880120 creator A5021376490 @default.
• W2077880120 creator A5027397339 @default.
• W2077880120 creator A5028366409 @default.
• W2077880120 creator A5028372834 @default.
• W2077880120 creator A5044951717 @default.
• W2077880120 creator A5053218727 @default.
• W2077880120 creator A5053293767 @default.
• W2077880120 creator A5060132287 @default.
• W2077880120 creator A5061657442 @default.
• W2077880120 creator A5072333489 @default.
• W2077880120 creator A5080617054 @default.
• W2077880120 date "2009-12-10" @default.
• W2077880120 modified "2023-09-27" @default.
• W2077880120 title "Abstract C132: Effect of hepatic or renal impairment on the pharmacokinetics of casopitant" @default.
• W2077880120 doi "https://doi.org/10.1158/1535-7163.targ-09-c132" @default.
• W2077880120 hasPublicationYear "2009" @default.
• W2077880120 type Work @default.
• W2077880120 sameAs 2077880120 @default.
• W2077880120 citedByCount "0" @default.
• W2077880120 crossrefType "proceedings-article" @default.
• W2077880120 hasAuthorship W2077880120A5021376490 @default.
• W2077880120 hasAuthorship W2077880120A5027397339 @default.
• W2077880120 hasAuthorship W2077880120A5028366409 @default.
• W2077880120 hasAuthorship W2077880120A5028372834 @default.
• W2077880120 hasAuthorship W2077880120A5044951717 @default.
• W2077880120 hasAuthorship W2077880120A5053218727 @default.
• W2077880120 hasAuthorship W2077880120A5053293767 @default.
• W2077880120 hasAuthorship W2077880120A5060132287 @default.
• W2077880120 hasAuthorship W2077880120A5061657442 @default.
• W2077880120 hasAuthorship W2077880120A5072333489 @default.
• W2077880120 hasAuthorship W2077880120A5080617054 @default.
• W2077880120 hasConcept C112705442 @default.
• W2077880120 hasConcept C126322002 @default.
• W2077880120 hasConcept C134018914 @default.
• W2077880120 hasConcept C159641895 @default.
• W2077880120 hasConcept C22979827 @default.
• W2077880120 hasConcept C2780306776 @default.
• W2077880120 hasConcept C2780580376 @default.
• W2077880120 hasConcept C2780852908 @default.
• W2077880120 hasConcept C71924100 @default.
• W2077880120 hasConcept C90924648 @default.
• W2077880120 hasConceptScore W2077880120C112705442 @default.
• W2077880120 hasConceptScore W2077880120C126322002 @default.
• W2077880120 hasConceptScore W2077880120C134018914 @default.
• W2077880120 hasConceptScore W2077880120C159641895 @default.
• W2077880120 hasConceptScore W2077880120C22979827 @default.
• W2077880120 hasConceptScore W2077880120C2780306776 @default.
• W2077880120 hasConceptScore W2077880120C2780580376 @default.
• W2077880120 hasConceptScore W2077880120C2780852908 @default.
• W2077880120 hasConceptScore W2077880120C71924100 @default.
• W2077880120 hasConceptScore W2077880120C90924648 @default.
• W2077880120 hasLocation W20778801201 @default.
• W2077880120 hasOpenAccess W2077880120 @default.
• W2077880120 hasPrimaryLocation W20778801201 @default.
• W2077880120 hasRelatedWork W1575739478 @default.
• W2077880120 hasRelatedWork W1967774979 @default.
• W2077880120 hasRelatedWork W1988546203 @default.
• W2077880120 hasRelatedWork W1996257503 @default.
• W2077880120 hasRelatedWork W2081847353 @default.
• W2077880120 hasRelatedWork W2084982405 @default.
• W2077880120 hasRelatedWork W2092534997 @default.
• W2077880120 hasRelatedWork W2120821524 @default.
• W2077880120 hasRelatedWork W2326526374 @default.
• W2077880120 hasRelatedWork W2564837419 @default.
• W2077880120 hasRelatedWork W2567222958 @default.
• W2077880120 hasRelatedWork W2583940696 @default.
• W2077880120 hasRelatedWork W2930255358 @default.
• W2077880120 hasRelatedWork W2998388546 @default.
• W2077880120 hasRelatedWork W3037821464 @default.
• W2077880120 hasRelatedWork W3048405075 @default.
• W2077880120 hasRelatedWork W3124565589 @default.
• W2077880120 hasRelatedWork W3129050812 @default.
• W2077880120 hasRelatedWork W3135972377 @default.
• W2077880120 hasRelatedWork W2889153989 @default.
• W2077880120 isParatext "false" @default.
• W2077880120 isRetracted "false" @default.
• W2077880120 magId "2077880120" @default.
• W2077880120 workType "article" @default.